AUROPHARMA Stock Overview
A biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
No risks detected for AUROPHARMA from our risk checks.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Aurobindo Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,133.40 |
| 52 Week High | ₹1,592.00 |
| 52 Week Low | ₹1,010.00 |
| Beta | 0.54 |
| 1 Month Change | 1.95% |
| 3 Month Change | -1.98% |
| 1 Year Change | 2.01% |
| 3 Year Change | 69.00% |
| 5 Year Change | 76.47% |
| Change since IPO | 1,593.03% |
Recent News & Updates
Aurobindo Pharma Limited (NSE:AUROPHARMA) Doing What It Can To Lift Shares
Mar 28
If EPS Growth Is Important To You, Aurobindo Pharma (NSE:AUROPHARMA) Presents An Opportunity
Feb 26Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 10Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 24Recent updates
Aurobindo Pharma Limited (NSE:AUROPHARMA) Doing What It Can To Lift Shares
Mar 28If EPS Growth Is Important To You, Aurobindo Pharma (NSE:AUROPHARMA) Presents An Opportunity
Feb 26Aurobindo Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Feb 10Calculating The Fair Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Jan 24
Penicillin G Ramp-Up And Biosimilar Breakthroughs To Propel Revenue Growth And Boost Net Margins
Jan 05 Strategic focus on new product launches and U.S. pricing stability can drive revenue growth while improving EBITDA margins.Is Aurobindo Pharma (NSE:AUROPHARMA) Using Too Much Debt?
Dec 18Earnings Miss: Aurobindo Pharma Limited Missed EPS By 14% And Analysts Are Revising Their Forecasts
Nov 12Insufficient Growth At Aurobindo Pharma Limited (NSE:AUROPHARMA) Hampers Share Price
Oct 20Estimating The Intrinsic Value Of Aurobindo Pharma Limited (NSE:AUROPHARMA)
Sep 10This Is Why Aurobindo Pharma Limited's (NSE:AUROPHARMA) CEO Can Expect A Bump Up In Their Pay Packet
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Aurobindo Pharma Limited (NSE:AUROPHARMA) Price Target To ₹1,422
Aug 13Here's Why Aurobindo Pharma (NSE:AUROPHARMA) Can Manage Its Debt Responsibly
Jun 20Aurobindo Pharma Limited (NSE:AUROPHARMA) Released Earnings Last Week And Analysts Lifted Their Price Target To ₹1,271
May 29Is Aurobindo Pharma Limited (NSE:AUROPHARMA) Expensive For A Reason? A Look At Its Intrinsic Value
May 22Shareholder Returns
| AUROPHARMA | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 7.1% | 5.1% | 5.3% |
| 1Y | 2.0% | 12.9% | 2.1% |
Return vs Industry: AUROPHARMA underperformed the Indian Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: AUROPHARMA matched the Indian Market which returned 1.5% over the past year.
Price Volatility
| AUROPHARMA volatility | |
|---|---|
| AUROPHARMA Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 7.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.9% |
Stable Share Price: AUROPHARMA has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: AUROPHARMA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 26,015 | Kambam Reddy | www.aurobindo.com |
Aurobindo Pharma Limited, a biopharmaceutical company, engages in the manufacture of generic formulations and active pharmaceutical ingredients in India, the United States of America, Europe, Puerto Rico, and internationally. The company offers formulation in form of oral solids, liquids, injectables, and vaccines, as well as over-the-counter drugs; and active pharmaceutical ingredients (APIs), biosimilars, biocatalysts, peptides, and hormones targeting key therapeutic areas, including central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and provides project-based chemistry contract services that cover the clinical stage through to manufacturing and management of the entire drug lifecycle in the API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams.
Aurobindo Pharma Limited Fundamentals Summary
| AUROPHARMA fundamental statistics | |
|---|---|
| Market cap | ₹658.28b |
| Earnings (TTM) | ₹34.91b |
| Revenue (TTM) | ₹309.22b |
18.9x
P/E Ratio2.1x
P/S RatioIs AUROPHARMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AUROPHARMA income statement (TTM) | |
|---|---|
| Revenue | ₹309.22b |
| Cost of Revenue | ₹130.42b |
| Gross Profit | ₹178.80b |
| Other Expenses | ₹143.89b |
| Earnings | ₹34.91b |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 60.11 |
| Gross Margin | 57.82% |
| Net Profit Margin | 11.29% |
| Debt/Equity Ratio | 27.3% |
How did AUROPHARMA perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield0%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 00:46 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aurobindo Pharma Limited is covered by 56 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Meeta Shetty | Asian Markets Securities Private Limited |
| Kamlesh Kotak | Asian Markets Securities Private Limited |
| Vijayaraghavan Swaminathan | Avendus Spark |